Skip to content
Menu

Wells Fargo Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $925

Benzinga Newsdesk 2 weeks ago

Analyst RatingsNewsPrice TargetHot

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Wells Fargo analyst Mohit Bansal maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $750 to $925.

Wells Fargo analyst Mohit Bansal maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $750 to $925.

Read at benzinga.com

← All stock news